- Home
- FORR vs TSHA Comparison
FORR vs TSHA Comparison
Compare FORR & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORR
- TSHA
- Stock Information
- Founded
- FORR 1983
- TSHA 2019
- Country
- FORR United States
- TSHA United States
- Employees
- FORR N/A
- TSHA N/A
- Industry
- FORR Diversified Commercial Services
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- FORR Consumer Discretionary
- TSHA Health Care
- Exchange
- FORR Nasdaq
- TSHA Nasdaq
- Market Cap
- FORR 297.7M
- TSHA 313.6M
- IPO Year
- FORR 1996
- TSHA 2020
- Fundamental
- Price
- FORR $15.19
- TSHA $1.53
- Analyst Decision
- FORR
- TSHA Strong Buy
- Analyst Count
- FORR 0
- TSHA 8
- Target Price
- FORR N/A
- TSHA $6.63
- AVG Volume (30 Days)
- FORR 52.0K
- TSHA 2.3M
- Earning Date
- FORR 02-06-2025
- TSHA 11-13-2024
- Dividend Yield
- FORR N/A
- TSHA N/A
- EPS Growth
- FORR N/A
- TSHA N/A
- EPS
- FORR N/A
- TSHA N/A
- Revenue
- FORR $442,518,000.00
- TSHA $9,915,000.00
- Revenue This Year
- FORR N/A
- TSHA N/A
- Revenue Next Year
- FORR $1.57
- TSHA N/A
- P/E Ratio
- FORR N/A
- TSHA N/A
- Revenue Growth
- FORR N/A
- TSHA N/A
- 52 Week Low
- FORR $13.96
- TSHA $1.19
- 52 Week High
- FORR $27.11
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- FORR 46.54
- TSHA 34.16
- Support Level
- FORR $14.37
- TSHA $1.56
- Resistance Level
- FORR $16.10
- TSHA $1.75
- Average True Range (ATR)
- FORR 0.54
- TSHA 0.16
- MACD
- FORR 0.00
- TSHA -0.02
- Stochastic Oscillator
- FORR 57.48
- TSHA 3.57
About FORR Forrester Research Inc.
Forrester Research Inc is a United States-based company that provides independent research, data, and advisory services. It operates through the following segments: The Research segment develops and delivers research, connect, and analytics products; The consulting segment includes the revenues and the related costs of the company's consulting organization, and the Events segment is engaged in developing and hosting in-person and virtual events.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.